- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04084457
Investigating the Effects of Daily Consumption of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance (BluFlow)
Randomised, Double-blind, Placebo Controlled, Parallel Trial Investigating the Daily Effects of Blueberry (Poly)Phenol Consumption on Vascular Function and Cognitive Performance in Healthy Elderly Individuals
Foods rich in certain (poly)phenols, particularly flavonoids, such as berries and cocoa, have been shown to improve measures of vascular function as well as cognitive performance in human intervention studies. This is a randomized, double-blind, placebo controlled, parallel trial investigating the effects of daily blueberry (poly)phenol consumption on vascular function and cognitive performance in healthy elderly individuals. The study will be conducted at King's College London, Franklin-Wilkins Building.
Eligible subjects will be healthy males and females aged 65-80.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To date no study has investigated whether daily blueberry consumption can induce an increase in cerebral blood flow, with subsequent improvements in vascular and cognitive function. In this study, the investigators aim to directly link daily blueberry consumption with improved vascular function, increased cerebral blood flow and positive cognitive outcomes in healthy elderly individuals. The investigators will use a large group of elderly individuals' representative of a healthy population, both males and females, aged 65-80 years to evaluate the health effects of daily blueberry consumption.
The main aim is to investigate whether improvements in vascular and cognitive function previously seen after blueberry consumption can be seen following 3-months daily consumption in elderly individuals, and whether enhanced cognitive performance is correlated with increased cerebral blood flow. The investigators hypothesise that daily consumption of an anthocyanin rich blueberry drink will improve cognitive performance and vascular function, increasing cerebral blood flow, in healthy older individuals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 9NH
- Franklin-Wilkins Building, King's College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants will include 60 healthy male and female volunteers, aged 65-80.
- Volunteers will be able to understand the nature of the study and able to give signed written informed consent.
- Subjects willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study.
Exclusion Criteria:
- Manifest cardiovascular diseases including coronary artery disease, cerebrovascular disease and peripheral artery disease.
- Hypertensive, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg.
- Obese participants, defined as BMI superior or equal to 30.
- Diabetes mellitus and metabolic syndrome.
- Acute inflammation, terminal renal failure or malignancies.
- Allergies to berries or another significant food allergy.
- Subjects under medication or on vitamin/dietary supplements (within 2 weeks of baseline).
- Subjects who have lost more than 10% of their weight in the past 6 months or are currently on a diet.
- Subjects who reported participant in another study within one month before the study starts.
- Subjects who smoke cigarettes irregularly.
- MCI or dyslexic or unable to complete the cognitive function tasks for any reason such as visual impairments.
- Subjects who require chronic antimicrobial or antiviral treatment.
- Subjects with unstable psychological condition.
- Subjects with history of cancer, myocardial infarction, cerebrovascular incident.
- Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Matched for macronutrients, micronutrients and fibre
|
Identical formulation as the treatment matched for fibre and vitamin C
|
|
Active Comparator: Wild Blueberry Powder
Formulation of a 100% blueberry (freeze-dried whole fruit) drink
|
Powdered extract obtained from wild blueberries.
A daily administration of 27g wild blueberry powder will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial Function
Time Frame: Baseline and 12 weeks post-intervention
|
Changes in flow-mediated dilation of the brachial artery (FMD) from baseline after 12-week consumption of blueberry vs control
|
Baseline and 12 weeks post-intervention
|
|
Cognitive function
Time Frame: Baseline and 12 weeks post-intervention
|
Changes in cognitive function from baseline after 12-week consumption of blueberry vs control.
Cognitive testing involves the participant conducting tasks administered on a tablet-style laptop.
The participants will be conducting these tasks whilst cerebral blood flow measurements are taking place.
The cognitive testing battery will consist of 4 tasks which are Auditory Verbal learning task, Corsi Blocks, Switching task and Serials 3's and 7's, including a mood assessment (PANAS).
|
Baseline and 12 weeks post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral blood flow velocity (CBFv)
Time Frame: Baseline and 12 weeks post-intervention
|
Changes in cerebral blood flow velocity (CBFv) from baseline after 12-week consumption of blueberry vs control.
Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD).
Variables measured include resting and active mean blood flow velocity (cm/s).
|
Baseline and 12 weeks post-intervention
|
|
Office systolic blood pressure
Time Frame: Baseline and 12 weeks post-intervention
|
Changes from baseline office systolic blood pressure (mmHg) after 12-week consumption of blueberry vs control.
|
Baseline and 12 weeks post-intervention
|
|
Pulse wave velocity (PWV)
Time Frame: Baseline and 12 weeks post-intervention
|
Determine the changes in Pulse wave velocity (PWV) from baseline after 12-week consumption of blueberry vs control.
|
Baseline and 12 weeks post-intervention
|
|
Augmentation Index (AIx)
Time Frame: Baseline and 12 weeks post-intervention
|
Changes in augmentation Index (AIx) using a Sphygmocor device post consumption of a placebo or blueberry treatment
|
Baseline and 12 weeks post-intervention
|
|
24-hour ambulatory systolic blood pressure
Time Frame: Baseline and 12 weeks post-intervention
|
Determine the effect of the blueberry extract vs Placebo on 24-hour systolic blood pressure using a monitor, at 12 weeks post consumption.
Variables include mean asleep, awake and total 24 h systolic blood pressure
|
Baseline and 12 weeks post-intervention
|
|
Mood
Time Frame: Baseline and 12 weeks post-intervention
|
Assessment using a self-reported questionnaire using the Positive and Negative Affect Schedule (PANAS).PANAS (The Positive and Negative Affect Schedule) to measure mood, where the participants will need to answer 20 questions using a 5-point likert scale that ranges from (1) not at all to (5) extremely.
Dependent variables are composite positive affect and negative affect scores obtained by summing responses to positive or negative PANAS items, respectively.
|
Baseline and 12 weeks post-intervention
|
|
Change in Blood lipids concentration (Total, HDL and LDL cholesterol, triglycerides)
Time Frame: Baseline and 12 weeks post-intervention
|
Determine the effect of the blueberry extract vs Placebo on blood lipids (Total, HDL and LDL cholesterol, triglycerides), at 12 weeks post consumption.
|
Baseline and 12 weeks post-intervention
|
|
Plasma blueberry (poly)phenol metabolites
Time Frame: Baseline and 12 weeks post-intervention
|
Measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours post consumption
|
Baseline and 12 weeks post-intervention
|
|
Microbiome analysis
Time Frame: Baseline and 12 weeks post-intervention
|
Stool sample collection involving an all-in-one kit for self-collection and stabilization of microbial DNA from faeces for gut microbiome profiling.
|
Baseline and 12 weeks post-intervention
|
|
Urine blueberry polyphenol metabolites
Time Frame: Baseline and 12 weeks post-intervention
|
Collected over a 24 hour period.
Measured by liquid chromotography- mass spectrometry (LC/MS) 0 and 2 hours post consumption
|
Baseline and 12 weeks post-intervention
|
|
Number of volunteers with treatment-related adverse events
Time Frame: Baseline and 12 weeks post-intervention
|
The number of volunteers with treatment-related adverse events will be assessed by questionnaires and interviews.
|
Baseline and 12 weeks post-intervention
|
|
Pulsatility index (PI)
Time Frame: Baseline and 12 weeks post-intervention
|
Changes in pulsatility index (PI) from baseline after 12-week consumption of blueberry vs control.
Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD).
Variables measured include resting and active PI (cm/s.
|
Baseline and 12 weeks post-intervention
|
|
Office diastolic blood pressure
Time Frame: Baseline and 12 weeks post-intervention
|
Changes from baseline office diastolic blood pressure (mmHg) after 12-week consumption of blueberry vs control.
|
Baseline and 12 weeks post-intervention
|
|
24-hour ambulatory diastolic blood pressure
Time Frame: Baseline and 12 weeks post-intervention
|
Determine the effect of the blueberry extract vs Placebo on 24-hour diastolic blood pressure using a monitor, at 12 weeks post consumption.
Variables include mean asleep, awake and total 24 h diastolic blood pressure
|
Baseline and 12 weeks post-intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ana Rodriguez-Mateos, PhD, Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BluFlow
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
Atisama TherapeuticsRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States